

VÉTOQUINOL PUBLISHES ITS REGISTRATION DOCUMENT AND ITS ANNUAL FINANCIAL REPORT RELATIVE TO FISCAL YEAR 2014 (FRENCH VERSION)

The **registration document** of Vétoquinol relative to fiscal year 2014, including the **annual financial report** relative to fiscal year 2014, was filed with the *Autorité des marchés financiers* (“the AMF”) on April 17, 2015.

It can be read or downloaded on the websites of:

- Vétoquinol (www.vetoquinol.com)
- the AMF (www.amf-france.org)

It is also available to the public free of charge upon simple request:

- by mail: **Vétoquinol**
Communication financière
Magny-Vernois – BP 189 – 70204 Lure Cedex - France
- by e-mail: relations.investisseurs@vetoquinol.com
- by phone: +33 (0)3 84 62 59 88

The registration document integrates among other:

- the report of the President of the Board of directors on the corporate governance and on the internal control established upon provisions of article L. 225-37 of the French Commercial code;
- the management report;
- the sustainable development report;
- the statutory auditors' reports;
- the information relative to the fees paid to the statutory auditors.

Next update: 2015 half-year results, July 30, 2015 after market close

About Vétoquinol

Vétoquinol is a leading global player in the animal health sector serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.

An independent pure player, Vétoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vétoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vétoquinol employs over 2,004 people.

Vétoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).

For more information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For more information, contact:

VETOQUINOL

Investor Relations

Marie-Josée Aubry-Rota

Tel.: +33 3 84 62 59 88

relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor and Media Relations

Emmanuel DOVERGNE

Tel.: +33 1 56 43 44 63

emmanuel.dovergne@keima.fr